Peripheral Vascular Devices And Accessories Market Size & Share Analysis - Growth Trends and Forecast (2026 - 2031)

Global Peripheral Vascular Devices And Accessories Market Trends and Insights

Rising PAD Prevalence in Ageing Population

More than 20 million U.S. adults live with PAD, and growth in the 65-plus population is increasing procedure volumes. Elderly patients frequently present multivessel, calcified lesions that require premium drug-coated balloons, bio-absorbable scaffolds and advanced atherectomy tools. Medicare reimbursement for outpatient vascular interventions broadens access, and hospital networks lean on same-day discharge pathways to manage capacity. Demand for patient-specific grafts is rising because anatomical variability increases with age, supporting early adoption of 3-D-printed or tissue-engineered options. Collectively, the demographic wave sustains double-digit growth in the high-value device sub-segments of the peripheral vascular devices and accessories market.

Preference for Minimally Invasive Endovascular Therapy

Clinical evidence indicates that endovascular approaches reduce complications and speed recovery compared with open surgery, with ASCs emerging as the fastest-growing site of service and spurring compact, integrated device designs, while drug-coated balloons and intravascular lithotripsy catheters deliver hospital-level outcomes without major capital outlays, and CMS now provides distinct outpatient reimbursement codes for these technologies. As payers lean on bundled payments, suppliers that bundle devices, navigation software and post-procedure monitoring apps gain negotiating leverage.

Favourable Reimbursement for Drug-Eluting Stents & Balloons

In July 2024 CMS created new device pass-through categories that top up payments when facilities use innovative peripheral devices, giving early-mover manufacturers clear economic headroom ^{[1]Source: Centers for Medicare & Medicaid Services, “July 2024 Hospital Outpatient Prospective Payment System Update,” cms.gov} . U.S. policy aligns with the EU’s hospital funding models that reward lower re-intervention rates, boosting uptake of long-acting drug-eluting stents (DES) and balloons (DEB). Established vendors that published five-year patency data lock in coding advantages, while late entrants face steeper data demands under EU-MDR. Reimbursement certainty also underpins premium pricing, enabling firms to channel margin into next-generation polymer coatings and sustained-release drug platforms for the peripheral vascular devices and accessories market.

AI-Guided Intravascular Imaging Catheters Boost Procedural Success

AI-enabled systems automatically extract vessel diameter, plaque composition and flow reserve data in real time, allowing operators to optimize balloon sizing and stent placement. FDA-cleared platforms such as AVVIGO demonstrated a 26% drop in target-vessel failure when imaging guidance informed therapy choices. The technology simultaneously reduces fluoroscopy time and contrast load, attractive benefits for frail renal patients. AI workflow analytics feed into remote mentoring dashboards, opening skill-transfer pathways in underserved regions. Vendors able to fuse imaging, AI and therapeutic delivery on a single console position themselves as system partners rather than product suppliers in the peripheral vascular devices and accessories market.

Stringent US-FDA & EU-MDR Evidence Requirements

Since September 2024 European regulators demand deeper clinical datasets and ongoing post-market surveillance before renewing licenses, lengthening development timelines and raising compliance costs . The U.S. Quality System Regulation rewrite, effective February 2026, mirrors ISO 13485 and obliges manufacturers to document risk-management loops from design through end of life. Mid-size firms struggle to bankroll new randomized trials, which accelerates consolidation as they seek the shelter of multinationals’ regulatory infrastructures. While the bar deters fast followers, first movers with mature quality systems turn the compliance burden into a durable moat within the peripheral vascular devices and accessories market.

High Device Recall Incidence Hurting Clinician Confidence

Recent Class I recalls, such as the 7,820-unit pullback of the Pipeline Vantage Embolization Device, underscore safety concerns in complex delivery systems. Each public alert triggers extra training requirements, slows adoption curves and raises malpractice insurance costs for physicians. Hospitals respond with stricter value-analysis committee reviews, stretching sales cycles. Conversely, suppliers that can show single-digit complaint rates and real-time field-service dashboards win clinician loyalty. The recall climate also fuels demand for AI-driven procedural safeguards that flag atypical pressure gradients or embolic risk during use, supporting premium accessory sales in the peripheral vascular devices and accessories market.

*Our forecasts treat driver/restraint impacts as directional, not additive. The impact forecasts reflect baseline growth, mix effects, and variable interactions.

Segment Analysis

By Product Type: Device Dominance Faces Accessory Innovation

The device category accounted for 73.85% of peripheral vascular devices and accessories market share in 2025, anchored by percutaneous transluminal angioplasty (PTA) balloons and self-expanding stents with proven long-term patency. Drug-eluting formulations and next-generation nitinol architectures allow these workhorse products to defend unit prices even as hospitals push bulk-buy contracts. Atherectomy and thrombectomy systems deepen margins by addressing calcific, chronic total occlusion and venous thromboembolism cases that demand specialized toolkits. IVC filters and embolic-protection lines remain smaller niches, yet their critical safety roles secure formulary access.

Accessories, although accounting for only 26.15% of 2025 revenue, are projected to outpace the parent class at a 5.94% CAGR through 2031, thereby lifting the overall peripheral vascular devices and accessories market size trajectory. Hydrophilic-coated guidewires, torque-responsive catheters and steerable sheaths shorten procedure times in tortuous anatomy, directly translating into ASC throughput gains. Vascular closure devices such as MYNX CONTROL cut time-to-ambulation by more than 50%, aligning with value-based metrics. Compression systems and pressure-monitoring kits unlock post-discharge revenue streams and embed vendors deeper into episode-of-care economics.

By Application: PAD Leadership Challenged by Varicose-Vein Innovation

PAD commanded 44.72% of 2025 revenue after decades of clinical guideline support and payer familiarity. Five-year data from the IN.PACT Global study showed 69.4% freedom from target-lesion revascularization, supporting drug-coated balloon use in femoropopliteal disease. Hospitals continue to invest in IVL consoles that safely fracture calcium and expand lumen area without overheating or distal embolization.

Varicose-vein treatment is growing fastest at 6.55% CAGR to 2031, buoyed by office-based radiofrequency and endovenous laser ablation that require minimal capital outlay. Medicare utilization climbed from 0.3 to 2.6 procedures per 1,000 beneficiaries between 2017 and 2024, highlighting a robust shift toward cosmetic–functional hybrid care. Deep-vein thrombosis interventions also gain momentum as mechanical thrombectomy devices such as FlowTriever remove large clot burdens without thrombolytics. Hemodialysis-access maintenance remains a specialized segment; Wrapsody endoprosthesis showed 89.8% six-month primary patency, easing reintervention burdens for vascular surgeons.

By End User: Hospital Dominance Erodes to ASC Efficiency

Hospitals retained 61.28% revenue share in 2025 thanks to imaging suites, hybrid ORs and intensive-care backup needed for multilevel disease. However, fixed-cost pressure and value-based purchasing curb the pace of premium-device adoption. Instead, administrators negotiate multi-year, volume-based agreements that squeeze list prices across the peripheral vascular devices and accessories market.

ASCs capture the highest growth at 6.73% CAGR, catalyzed by physician ownership models and transparent bundled pricing that appeals to commercial insurers. Procedure migration spans from simple superficial venous work to complex iliac angioplasty as low-profile devices and imaging carts mature. Specialty vascular clinics add a third care tier, blending outpatient efficiency with focused expertise. Device makers that package balloons, closure systems and cloud-based reporting tools in single-invoice kits resonate strongly with ASC buyers.

Geography Analysis

North America delivered 39.92% of global revenue in 2025, powered by early reimbursement for breakthrough devices such as Abbott’s Esprit BTK dissolving scaffold and Humacyte’s SYMVESS tissue-engineered vessel . The region’s hospitals adopt predictive analytics to flag restenosis risk, and payers expand peripheral bundles that reward durable patency. M&A activity—Stryker’s USD 4.9 billion Inari purchase and Boston Scientific’s serial bolt-ons—reflect scale plays to defend share amid price compression. Canada and Mexico trail U.S. adoption curves by two to three years but accelerate catheter-lab capacity expansion under public-private partnership models.

Europe balances innovation leadership against intensified regulation. Full EU-MDR enforcement forces companies to run longer pivotal trials, stretching average approval timelines past 24 months. National health systems pivot to value-based procurement, pushing suppliers to package devices with training, registries and remote monitoring. Germany and the United Kingdom remain the top adopters of AI-guided imaging, while France channels stimulus funds into outpatient facility upgrades. Southern European nations emphasize cost-effective DES and guidewire kits to manage rising PAD burden without inflating hospital budgets.

Asia-Pacific is the fastest-growing theatre, set to grow at 7.05% CAGR through 2031. China’s central government is underwriting cath-lab rollouts in more than 120 tier-2 cities, directly fueling bulk tenders for balloons, stents and IVL consoles. Local manufacturing incentives reduce tariff barriers and encourage Western OEMs to form joint ventures for value-engineering. Japan’s super-aged society drives demand for low-contrast, low-radiation tools, and insurers reimburse IVL at hospital-outpatient parity to cut length of stay. India expands private cardiac-care chains, seeking mid-price devices that balance cost and durability, while Australia and South Korea prioritize AI-enabled guidance to offset interventional radiologist shortages. Collectively, the region reshapes competitive dynamics by favoring companies that tailor portfolios to diverse price points within the peripheral vascular devices and accessories market.

Regulatory Landscape

The regulatory environment is tightening around clinical evidence and quality-system compliance for peripheral vascular devices and accessories, which favors manufacturers with scale and established post-market infrastructure. In the United States, most peripheral catheters and related tools continue to route through Class II pathways, including 510(k). The FDA Quality Management System Regulation (QMSR) took effect on February 2, 2026, aligning 21 CFR Part 820 more closely with ISO 13485:2016 and increasing the documentation and risk-management bar across design, manufacturing, and lifecycle controls.

In Europe, EU-MDR conformity assessment remains constrained by Notified Body capacity and longer review cycles, adding time and cost to maintain certificates for legacy portfolios. On March 20, 2026, the European Commission adopted delegated regulations expanding the list of Well-Established Technologies (WET), including categories relevant to cardiovascular tools such as certain catheters and guidewires. This provides a clearer route for qualifying technologies to avoid new pre-market clinical investigations while still meeting MDR requirements. Ongoing vigilance remains important, as shown by a March 3, 2026 voluntary Class 2 recall by AngioDynamics for Soft-Vu angiographic catheters tied to a manufacturing defect, which reinforced the market-wide focus on manufacturing controls and post-market surveillance.

Market Opportunities and Future Outlook

Opportunities concentrate in higher-acuity peripheral disease segments, where new indications and workflow efficiency can translate into differentiated purchasing value for hospitals and fast-growing ASCs. Deep venous disease stands out after FDA approval in January 2026 for W. L. Gore & Associates GORE VIABAHN FORTEGRA Venous Stent, the first device indicated for treatment of deep venous disease in the inferior vena cava (IVC), iliac, and iliofemoral veins. This expands the addressable population for dedicated venous stenting and lifts demand for compatible access, imaging, and closure accessories.

Below-the-knee chronic limb-threatening ischemia (CLTI) and long-lesion PAD also create whitespace for anatomically specific, procedure-streamlining designs. In July 2026, Abbott received FDA approval for a longer-length (76 mm) Esprit BTK system targeting long BTK lesions with fewer device exchanges and shorter procedural workflows, aligning with outpatient migration and value-based purchasing pressure. Across arterial and venous interventions, manufacturers are also investing in evidence generation and multimodal guidance, with growing emphasis on IVUS-assisted sizing and deployment, and on platforms such as bioresorbable scaffolds and conformable polymer architectures. These trends support integrated portfolios that bundle therapy devices with steerable access, imaging-compatible consumables, and closure systems.